PSTV PLUS THERAPEUTICS Inc.

2.47
-0.27  -10%
Previous Close 2.74
Open 2.65
52 Week Low 0.931
52 Week High 22.89
Market Cap $10,555,999
Shares 4,273,857
Float 4,111,173
Enterprise Value $8,659,832
Volume 222,579
Av. Daily Volume 504,795
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
Rhenium NanoLiposomes (ReSPECT)
Glioma
Phase 1/2
Phase 1/2
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.

Drug Pipeline

Drug Stage Notes
DocePLUS (ATI-1123)
Platinum-sensitive small cell lung cancer
Phase 2
Phase 2
Phase 2 trial to be initiated 2H 2020.

Latest News

  1. AUSTIN, Texas, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), today announced financial and business results for its Second Quarter Fiscal Year 2020 ended June 30, 2020.

    Q2 2020 net loss was $1.8 million, or $0.45 per share, including payments to NanoTx LLC of $0.78 million. Net cash used in operating activities for the six months ended June 30, 2020 was approximately $2.9 million. Plus Therapeutics ended Q2 2020 with approximately $9.3 million of cash and cash equivalents.

    The Plus Therapeutics portfolio has three clinical-stage injectable drugs being developed on a unique nanotechnology platform designed to provide patient benefits through improved formulation and delivery…

    AUSTIN, Texas, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), today announced financial and business results for its Second Quarter Fiscal Year 2020 ended June 30, 2020.

    Q2 2020 net loss was $1.8 million, or $0.45 per share, including payments to NanoTx LLC of $0.78 million. Net cash used in operating activities for the six months ended June 30, 2020 was approximately $2.9 million. Plus Therapeutics ended Q2 2020 with approximately $9.3 million of cash and cash equivalents.

    The Plus Therapeutics portfolio has three clinical-stage injectable drugs being developed on a unique nanotechnology platform designed to provide patient benefits through improved formulation and delivery innovation. The Company believes the platform can enable significant potential enhancements of safety, efficacy and convenience for oncology patients and their health providers compared to current standards of care.

    The lead investigational drug in the Company's licensed radiotherapeutic portfolio is Rhenium NanoLiposomes (RNL), a nanoliposome-encapsulated radionuclide for several cancer targets.  Initially being developed for the treatment of recurrent glioblastoma, RNL is being evaluated in the U.S. NIH/NCI-supported, multi-center ReSPECT™ Phase 1 dose-finding clinical trial (NCT01906385).  RNL is designed to safely, effectively, and conveniently deliver a very high dose of radiation directly into the brain tumor that is up to 25 times greater than that currently being given to recurrent glioblastoma patients using external beam radiation therapy.

    H2 2020 Business Expansion Outlook

    The first half of Fiscal Year 2020 marked the successful implementation of the Company's refined development focus, initial pipeline expansion and optimized cost structure. In the second half of Fiscal Year 2020, the Company intends to focus on a number of additional business objectives and potential milestones:

    • Report preliminary RNL™ data from the ReSPECT Phase I dose finding trial in recurrent glioblastoma
    • Finalize RNL Phase 2/pivotal trial plan in recurrent glioblastoma
    • Seek RNL Orphan Drug Designation decisions from regulatory agencies
    • Complete evaluations of additional external and internal drug development candidates
    • Initiate IND-enabling RNL studies for additional indications
    • Explore partnership opportunities for RNL, DocePLUS and DoxoPLUS assets

    "Following the close of our most recent in-licensing transaction, we have made steady progress in expediting the ReSPECT trial," said Dr. Marc Hedrick, President and Chief Executive Officer of Plus Therapeutics.  "The second half of 2020 includes the prospect of further significant advancement for our RNL program-- and for the Company. We believe RNL has the potential of improving brain tumor therapy and that of other difficult to treat radiosensitive tumors."

    Q2 2020 Financial Highlights

    • Net cash used in operating activities was $2.9 million for the six months ended June 30, 2020, compared to $4.4 million during the same period in 2019.
    • In Q2 2020, 162,500 series U warrants were exercised, raising $0.36M.
    • Q2 2020 loss from continuing operations was $1.8 million, or $ 0.45 per share, compared to $2.3 million, or $5.12 per share for Q2 2019.
    • Q2 2020 net loss was $1.8 million, or $0.45 per share, compared to $9.1 million, or $20.67 per share, for Q2 2019, reflecting a loss from discontinued operations of $0 for Q2 2020 and $6.9 million in Q2 2019.

    Investor Call Today at 5 p.m. EDT

    The Company plans to hold a conference call and live audio webcast today at 5:00 PM Eastern Time to discuss its financial results and provide a general business update.

    Event:Plus Therapeutics Second Quarter Fiscal Year 2020 Financial Results Conference Call and Webcast
    Date:Monday, August 10, 2020
    Time: 5:00 PM Eastern Time.
    Live Call:Phone Number: (877) 402-3914; Conference ID:  5925129 
    Live Webcast:https://event.on24.com/wcc/r/2402905/A6C80D40192BA72B1FDF935FEAFD7277
     Beginning two hours after the conclusion of the conference call, a replay will be available. 
    Replay:http://ir.plustherapeutics.com/events/default.aspx

    About Plus Therapeutics, Inc.

    Plus Therapeutics (NASDAQ:PSTV) is a clinical-stage pharmaceutical company whose radiotherapeutic portfolio is concentrated on nanoliposome-encapsulated radionuclides for several cancer targets. Central to the Company's drug development is a unique nanotechnology platform designed to reformulate, deliver and commercialize multiple drugs targeting rare cancers and other diseases. The platform is designed to facilitate new delivery approaches and/or formulations of safe and effective, injectable drugs, potentially enhancing the safety, efficacy and convenience for patients and healthcare providers. More information may be found at www.plustherapeutics.com and www.respect-trials.com

    Cautionary Statement Regarding Forward-Looking Statements

    This press release contains statements that may be deemed "forward-looking statements" within the meaning of U.S. securities laws. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as "will," "believe," "plan," "can," "enable," "design," "intend," "potential," "expect," "estimate," "project," "prospect," "target," "focus," "anticipate," "could," "should," and similar expressions or the negatives thereof.  Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements regarding the following: the design and potential of the Plus Therapeutics portfolio to reformulate, deliver and commercialize multiple novel, proprietary drugs targeting rare cancers and other diseases and to facilitate new delivery approaches and/or formulations of safe and effective, injectable drugs; the Company's belief as to the platform's capacity to leverage new delivery approaches and/or formulations to enable significant potential enhancements of safety, efficacy and convenience for patients and healthcare providers; the potential of the Company's portfolio generally, and the potential of RNL™ to safely and effectively deliver a dose of radiation directly to the tumor up to 25 times greater than that currently being given to patients using external beam radiation therapy; the Company's belief as to the potential of RNL™ to improve brain tumor therapy and that of other difficult to treat radiosensitive tumors; the timing, status, outcome, and anticipated expansion of clinical trials for RNL™, including the planned initiation of an additional Phase 1 study and enrollment at additional sites, and the anticipated timing thereof; the Company's business expansion outlook for the second half of 2020, including its intended focus on certain additional business expansion milestones; the Company's expectations regarding the progress and prospect of advancement for the Company, RNL™, and the Company's portfolio during the second half of 2020; and the potential impact of the COVID-19 pandemic on the Company and its clinical programs, operating results, and financial condition. The forward-looking statements included in this press release are subject to a number of risks and uncertainties that may cause actual results to differ materially from those discussed in such forward-looking statements.  These risks and uncertainties include, but are not limited to: the risk that the Company is not able to successfully develop product candidates that can leverage the U.S. FDA's accelerated regulatory pathways; the early stage of the Company's product candidates and therapies, the results of its research and development activities, including uncertainties relating to the clinical trials of its product candidates and therapies; the Company's history of losses; the Company's need for, and ability to raise, additional cash or obtain other sources of funding; the Company's ability to: (a) obtain and maintain regulatory approvals, (b) continue as a going concern, (c) remain listed on the Nasdaq Capital Market, (d) to obtain or maintain sufficient levels of reimbursement for its tests, and (d) to repay or refinance some or all of its outstanding indebtedness; the outcome of the Company's partnering/licensing efforts; market and economic conditions; the impact of the COVID-19 pandemic on the Company and the effectiveness of the efforts it has taken or may take in the future in response thereto; and additional risks described under the heading "Risk Factors" in the Company's Securities and Exchange Commission filings, including in the Company's annual and quarterly reports. There may be events in the future that the Company is unable to predict, or over which it has no control, and its business, financial condition, results of operations and prospects may change in the future. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so.

     
     
    PLUS THERAPEUTICS, INC.

    CONSOLIDATED CONDENSED BALANCE SHEETS

    (UNAUDITED)

    (in thousands, except share and par value data)
     
      As of June 30,

    2020
      As of December 31,

    2019
     
    Assets        
    Current assets:        
    Cash and cash equivalents $9,266  $17,552 
    Accounts receivable  951   1,169 
    Restricted cash     40 
    Inventories, net  107   107 
    Other current assets  469   957 
    Total current assets  10,793   19,825 
             
    Property and equipment, net  2,014   2,179 
    Operating lease right-of-use assets  707   781 
    Other assets  18   72 
    Goodwill  372   372 
    Total assets $13,904  $23,229 
    Liabilities and Stockholders' Equity        
    Current liabilities:        
    Accounts payable and accrued expenses $3,608  $3,279 
    Operating lease liability  139   147 
    Term loan obligations, net of discount  6,026   11,060 
    Total current liabilities  9,773   14,486 
             
             
    Noncurrent operating lease liability  589   646 
    Warrant liability  242   6,929 
    Other noncurrent liabilities     8 
    Total liabilities  10,604   22,069 
             
    Commitments and contingencies        
             
    Stockholders' equity:        
    Preferred stock, $0.001 par value; 5,000,000 shares authorized; 1,959 shares issued

    and outstanding at June 30, 2020 and December 31, 2019
          
    Common stock, $0.001 par value; 100,000,000 shares authorized; 4,273,857 and

    3,880,588 shares issued and outstanding at June 30, 2020 and December 31, 2019,

    respectively
      4   4 
    Additional paid-in capital  431,492   426,426 
    Accumulated deficit  (428,196)  (425,270)
    Total stockholders' equity  3,300   1,160 
    Total liabilities and stockholders' equity $13,904  $23,229 



    PLUS THERAPEUTICS, INC.

    CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

    (UNAUDITED)

    (in thousands, except share and per share data)
     
      For the Three Months Ended June 30,  For the Six Months Ended June 30, 
      2020  2019  2020  2019 
    Development revenues:                
    Government contracts and other $185  $302  $303  $1,039 
    Operating expenses:                
    Research and development  327   1,289   1,268   2,715 
    In process research and development acquired from NanoTx  781      781    
    Sales and marketing  105   97   215   211 
    General and administrative  1,324   875   2,832   2,237 
           Total operating expenses  2,537   2,261   5,096   5,163 
           Operating loss  (2,352)  (1,959)  (4,793)  (4,124)
                     
    Other income (expense):                
    Interest income  9   7   45   14 
    Interest expense  (252)  (597)  (601)  (1,111)
    Change in fair value of warrants  756   282   2,423   492 
          Total other income (expense)  513   (308)  1,867   (605)
    Loss from continuing operations  (1,839)  (2,267)  (2,926)  (4,729)
    Loss from discontinued operations     (6,880)     (7,568)
      Net loss $(1,839) $(9,147) $(2,926) $(12,297)
                     
    Basic and diluted net loss per share attributable to common stockholders - continuing operations $(0.45) $(5.12) $(0.74) $(11.89)
    Basic and diluted net loss per share attributable to common stockholders - discontinued operations $  $(15.55) $  $(19.02)
    Net loss per share, basis and diluted $(0.45) $(20.67) $(0.74) $(30.91)
    Basic and diluted weighted average shares used in calculating net loss per share attributable to common stockholders  4,053,242   442,512   3,967,392   397,827 
                     



    PLUS THERAPEUTICS, INC.

    CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS

    (UNAUDITED)

    (in thousands)
     
      For the Six Months Ended June 30, 
      2020  2019 
    Cash flows used in operating activities:        
    Net loss $(2,926) $(12,297)
    Adjustments to reconcile net loss to net cash used in operating activities:        
    Depreciation and amortization  188   617 
    Amortization of deferred financing costs and debt discount  275   257 
    In process research and development acquired from NanoTx Therapeutics  781    
    Noncash lease expenses  9   39 
    Change in fair value of warrants  (2,423)  (492)
    Share-based compensation expense  55   77 
    Loss on sale of business     6,508 
    Increases (decreases) in cash caused by changes in operating assets and liabilities:        
    Accounts receivable  218   (28)
    Inventories     235 
    Other current assets  487   216 
    Other assets  54   257 
    Accounts payable and accrued expenses  371   108 
    Deferred revenues     29 
    Other long-term liabilities     54 
        Net cash used in operating activities  (2,911)  (4,420)
    Cash flows provided by (used in) investing activities:        
    Purchases of property and equipment  (23)  (6)
    In process research and development acquired from NanoTx Therapeutics  (400)   
    Proceeds from sale of business     5,637 
        Net cash provided by (used in) investing activities  (423)  5,631 
    Cash flows used in financing activities:        
    Principal payments of long-term obligations  (5,307)  (3,490)
    Payment of financing lease liability  (51)  (28)
    Proceeds from exercise of warrants  366    
    Proceeds from sale of common stock, net     1,984 
        Net cash used in financing activities  (4,992)  (1,534)
        Effect of exchange rate changes on cash and cash equivalents     (4)
        Net decrease in cash and cash equivalents  (8,326)  (327)
    Cash, cash equivalents, and restricted cash at beginning of period  17,592   5,301 
    Cash, cash equivalents, and restricted cash at end of period $9,266  $4,974 
    Supplemental disclosure of cash flows information:        
    Cash paid during period for:        
    Interest $372  $826 
    Supplemental schedule of non-cash investing and financing activities:        
    Common stock issued in payment for in process research and development $381    
             

    Contact:

    Plus Therapeutics, Inc. 

    Andrew Sims

    VP – Chief Financial Officer, Investor Relations

    Phone: +1.619.333.4150

    Email: 

    Corporate Website: plustherapeutics.com

    Clinical Website:  respect-trials.com

    Primary Logo

    View Full Article Hide Full Article
  2. AUSTIN, Texas, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) (the "Company") today announced that it will report its Second Quarter Fiscal Year 2020 financial results after the close of market on August 10, 2020. The company plans to hold a conference call and live audio webcast at 5:00 PM Eastern Time to discuss its financial results and provide a general business update.

    Event:Plus Therapeutics Second Quarter Fiscal Year 2020 Financial Results Conference Call and Webcast.
    Date:Monday, August 10, 2020.
    Time:5:00 PM Eastern Time.
    Live Call:Phone Number: (877) 402-3914; Conference ID: 5925129
    Live Webcast:https://event.on24.com/wcc/r/2402905/A6C80D40192BA72B1FDF935FEAFD7277
    Beginning two hours after the conclusion of

    AUSTIN, Texas, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) (the "Company") today announced that it will report its Second Quarter Fiscal Year 2020 financial results after the close of market on August 10, 2020. The company plans to hold a conference call and live audio webcast at 5:00 PM Eastern Time to discuss its financial results and provide a general business update.

    Event:Plus Therapeutics Second Quarter Fiscal Year 2020 Financial Results Conference Call and Webcast.
    Date:Monday, August 10, 2020.
    Time:5:00 PM Eastern Time.
    Live Call:Phone Number: (877) 402-3914; Conference ID: 5925129
    Live Webcast:https://event.on24.com/wcc/r/2402905/A6C80D40192BA72B1FDF935FEAFD7277

    Beginning two hours after the conclusion of the conference call, a replay will be available.
    Replay:http://ir.plustherapeutics.com/events/default.aspx

    About Plus Therapeutics, Inc.

    Plus Therapeutics (NASDAQ:PSTV) is a clinical-stage pharmaceutical company whose radiotherapeutic portfolio is concentrated on nanoliposome-encapsulated radionucleotides for several cancer targets. Central to the Company's drug development is a unique nanotechnology platform designed to reformulate, deliver and commercialize multiple drugs targeting rare cancers and other diseases. The platform is designed to facilitate new delivery approaches and/or formulations of safe and effective, injectable drugs, potentially enhancing the safety, efficacy and convenience for patients and healthcare providers. More information may be found at www.plustherapeutics.com and www.respect-trials.com.

    Cautionary Statement Regarding Forward-Looking Statements

    This press release contains certain statements that may be deemed "forward-looking statements" within the meaning of U.S. securities laws. All statements, other than statements of historical fact, that address activities, events or developments that we intend, expect, project, believe or anticipate and similar expressions or future conditional verbs such as will, should, would, could or may occur in the future are forward-looking statements. Such statements are based upon certain assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements about: the Company's potential to facilitate new delivery approaches and/or formulations of safe and effective, injectable drugs, potentially enhancing the safety, efficacy and convenience for patients and healthcare providers; the Company's potential to develop drug candidates currently in its product pipeline; and the Company's potential to develop additional drugs outside of its current pipeline. The forward-looking statements included in this press release are subject to a number of additional material risks and uncertainties, including but not limited to: the risk that the Company is not able to successfully develop product candidates that can leverage the U.S. FDA's accelerated regulatory pathways; and the risks described under the heading "Risk Factors" in the Company's Securities and Exchange Commission filings, including in the Company's annual and quarterly reports. There may be events in the future that the Company is unable to predict, or over which it has no control, and its business, financial condition, results of operations and prospects may change in the future. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so.

    Contact:

    Plus Therapeutics, Inc. 

    Andrew Sims

    VP – Chief Financial Officer, Investor Relations

    Phone: +1.619.333.4150

    Email: 

    Website: plustherapeutics.com

    Clinical Website:  respect-trials.com

    Primary Logo

    View Full Article Hide Full Article
  3. AUSTIN, Texas, July 28, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company") today announced the successful completion of the fifth cohort of the ReSPECT Clinical Trial and expansion to a second clinical trial site, the UT Southwestern Medical Center in Dallas.

    The Phase 1 ReSPECT Clinical Trial is intended to assess the safety, tolerability, and distribution of a novel radiotherapy, Rhenium NanoLiposomes (RNL™), in adults with recurrent glioblastoma (GBM) after standard surgical, radiation, and chemotherapy treatment. ReSPECT is supported by an award from the National Cancer Institute through Phase 2 development. Glioblastoma is a rare, incurable, and fatal disease with a median survival of about nine months…

    AUSTIN, Texas, July 28, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company") today announced the successful completion of the fifth cohort of the ReSPECT Clinical Trial and expansion to a second clinical trial site, the UT Southwestern Medical Center in Dallas.

    The Phase 1 ReSPECT Clinical Trial is intended to assess the safety, tolerability, and distribution of a novel radiotherapy, Rhenium NanoLiposomes (RNL™), in adults with recurrent glioblastoma (GBM) after standard surgical, radiation, and chemotherapy treatment. ReSPECT is supported by an award from the National Cancer Institute through Phase 2 development. Glioblastoma is a rare, incurable, and fatal disease with a median survival of about nine months following recurrence despite the current standard of care.

    Patient screening and enrollment at UT Southwestern Medical Center is ongoing and will be led by principal investigator and neurosurgeon, Toral Patel, MD. "We are pleased to add the UT Southwestern Medical Center team led by Dr. Patel to our trial," said Dr. Andrew Brenner, MD, PhD, who is the principal investigator of the trial and is the Kolitz Chair in Neuro-Oncology Research and Co-Leader of the Experimental and Developmental Therapeutics Program at UT Health San Antonio MD Anderson Cancer Center. "Convection-enhanced delivery of RNL directly into the tumor represents a promising new local radiation treatment option for recurrent GBM patients." 

    Plans are underway to expand ReSPECT to another site, the MD Anderson Cancer Center in Houston. To-date, the study has enrolled 15 patients across five cohorts at the UT Health Science Center San Antonio, with one more cohort of six patients planned to fully complete enrollment.

    In ReSPECT, very high therapeutic doses of a high energy beta-emitting radioisotope, Rhenium-186, are precisely delivered directly into the brain tumor via stereotactic technology and convection-enhanced delivery (CED). Studies have demonstrated that CED holds great promise in terms of local drug penetration through the brain extracellular matrix/space. The local radiation delivered to the brain tumor with RNL is intended to be up to 25 times greater than that currently being given to patients using external beam radiation therapy (EBRT). Thus far, the highest absorbed radiation dose delivered to a patient's tumor in ReSPECT is approximately 15 times the level typically delivered by EBRT.

    The Company expects additional near-term ReSPECT and RNL developments to include:

    • Continued dose escalation and expansion of delivery parameters through cohort 6.
    • Completion of enrollment of the Phase 1 Trial.
    • Determination of the recommended Phase 2 dose.
    • Submission of applications for Orphan Disease Designation in the U.S. and Europe.
    • Submission of an application for Fast Track Designation in the U.S.
    • Data analysis and reporting of the ReSPECT Clinical Trial Results.
    • Presentation by the Company for plans to expand RNL clinical development for multiple indications.

    About Plus Therapeutics, Inc.

    Plus Therapeutics (NASDAQ:PSTV) is a clinical-stage pharmaceutical company whose radiotherapeutic portfolio is concentrated on nanoliposome-encapsulated radionucleotides for several cancer targets. Central to the Company's drug development is a unique nanotechnology platform designed to reformulate, deliver and commercialize multiple drugs targeting rare cancers and other diseases. The platform is designed to facilitate new delivery approaches and/or formulations of safe and effective, injectable drugs, potentially enhancing the safety, efficacy and convenience for patients and healthcare providers. More information may be found at www.plustherapeutics.com and www.respect-trials.com.

    Cautionary Statement Regarding Forward-Looking Statements

    This press release contains certain statements that may be deemed "forward-looking statements" within the meaning of U.S. securities laws. All statements, other than statements of historical fact, that address activities, events or developments that we intend, expect, project, believe or anticipate and similar expressions or future conditional verbs such as will, should, would, could or may occur in the future are forward-looking statements. Such statements are based upon certain assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements about: the Company's potential to facilitate new delivery approaches and/or formulations of safe and effective, injectable drugs, potentially enhancing the safety, efficacy and convenience for patients and healthcare providers; the Company's potential to develop drug candidates currently in its product pipeline; and the Company's potential to develop additional drugs outside of its current pipeline. The forward-looking statements included in this press release are subject to a number of additional material risks and uncertainties, including but not limited to: the risk that the Company is not able to successfully develop product candidates that can leverage the U.S. FDA's accelerated regulatory pathways; and the risks described under the heading "Risk Factors" in the Company's Securities and Exchange Commission filings, including in the Company's annual and quarterly reports. There may be events in the future that the Company is unable to predict, or over which it has no control, and its business, financial condition, results of operations and prospects may change in the future. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so.

    Contact:

    Plus Therapeutics, Inc. 

    Andrew Sims

    VP – Chief Financial Officer, Investor Relations

    Phone: +1.619.333.4150

    Email: 

    Corporate Website: plustherapeutics.com

    Clinical Website: respect-trials.com

    Primary Logo

    View Full Article Hide Full Article
  4. AUSTIN, Texas, July 23, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company") today announced that it will be presenting at the YAFO ACCESS CHINA - 2020 Summer Online Partnering Day on Thursday, July 30 at 10:00 pm EST.  Dr. Marc Hedrick, President and CEO of Plus Therapeutics, will be hosting the presentation and answering questions from investors.

    To access the live presentation, please use the following information:

    YAFO ACCESS CHINA Partnering Conference
    Date:Thursday, July 30, 2020
    Time:10:00 p.m. Eastern Time (7:00 p.m. Pacific Time)

    If you would like to register for the event, you may purchase a free Live Day Attendee Ticket or Video on Demand Attendee Ticket here:
    https://www.eventbrite.com/e/access-china-2020-summer-online-partnering-day-tickets-106868540682

    AUSTIN, Texas, July 23, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company") today announced that it will be presenting at the YAFO ACCESS CHINA - 2020 Summer Online Partnering Day on Thursday, July 30 at 10:00 pm EST.  Dr. Marc Hedrick, President and CEO of Plus Therapeutics, will be hosting the presentation and answering questions from investors.

    To access the live presentation, please use the following information:

    YAFO ACCESS CHINA Partnering Conference

    Date:Thursday, July 30, 2020
    Time:10:00 p.m. Eastern Time (7:00 p.m. Pacific Time)

    If you would like to register for the event, you may purchase a free Live Day Attendee Ticket or Video on Demand Attendee Ticket here:

    https://www.eventbrite.com/e/access-china-2020-summer-online-partnering-day-tickets-106868540682

    If investors are unable to make the live presentation, a replay-day will be arranged one week later and a link will be posted to the Company's website.

    About YAFO Life Science

    YAFO Life Science is the healthcare division of YAFO Capital, a Shanghai-based investment bank boutique and investment firm focused on Life Sciences. YAFO organizes every year ACCESS CHINA Forum event series providing online corporate access through its proprietary deal-making platform, which covers 2,000+ BD directors and executives from Chinese biopharma, healthcare, and investment firms. ACCESS CHINA creates invaluable BD opportunities by directly connecting and meeting with the right partners for development, licensing, or commercial collaborations. Together with its co-organizers and partners, YAFO Life Science helps Western biopharma companies efficiently present their assets online in front of 500+ healthcare companies and VCs in China.

    About Plus Therapeutics, Inc.

    Plus Therapeutics (NASDAQ:PSTV) is a clinical-stage pharmaceutical company whose radiotherapeutic portfolio is concentrated on nanoliposome-encapsulated radionucleotides for several cancer targets. Central to the Company's drug development is a unique nanotechnology platform designed to reformulate, deliver and commercialize multiple drugs targeting rare cancers and other diseases. The platform is designed to facilitate new delivery approaches and/or formulations of safe and effective, injectable drugs, potentially enhancing the safety, efficacy and convenience for patients and healthcare providers. More information may be found at www.plustherapeutics.com and at www.respect-trials.com

    Contact:

    Plus Therapeutics, Inc. 

    Andrew Sims

    VP – Chief Financial Officer, Investor Relations

    Phone: +1.619.333.4150

    Email: 

    Corporate Website: plustherapeutics.com

    Clinical Website: respect-trials.com

    Primary Logo

    View Full Article Hide Full Article
  5. AUSTIN, Texas, July 06, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) today announced that the compensation committee of the Company's board of directors approved an inducement grant of stock options to purchase a total of 40,000 shares of common stock to Dr. Gregory Stein with a grant date of June 29, 2020 and an exercise price equal to $2.11, the fair market value on the grant date and a total of an additional 40,000 shares of common stock to Andrew Sims with a grant date of February 6, 2020 and an exercise price equal to $2.23, the fair market value on the grant date.

    The options issued to Mr. Stein and Mr. Sims, respectively, have a ten year term and vest over four years, with 25% vesting on the one-year anniversary…

    AUSTIN, Texas, July 06, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) today announced that the compensation committee of the Company's board of directors approved an inducement grant of stock options to purchase a total of 40,000 shares of common stock to Dr. Gregory Stein with a grant date of June 29, 2020 and an exercise price equal to $2.11, the fair market value on the grant date and a total of an additional 40,000 shares of common stock to Andrew Sims with a grant date of February 6, 2020 and an exercise price equal to $2.23, the fair market value on the grant date.

    The options issued to Mr. Stein and Mr. Sims, respectively, have a ten year term and vest over four years, with 25% vesting on the one-year anniversary of the employee's first day of employment with the Company and 1/36 of the remaining shares vesting monthly thereafter, subject to Dr. Stein's and Mr. Sims' continued service relationship with the Company, respectively, on each such date. The options are being granted under the Company's 2015 New Employee Incentive Plan, which was amended on February 6, 2020 to add 250,000 additional shares of common stock to the pool of shares to be used exclusively for the grant of inducement awards in compliance with Nasdaq Listing Rule 5635(c)(4). The options issued to Dr. Stein and to Mr. Sims are subject to the terms and conditions of the Company's 2015 New Employee Incentive Plan and the stock option agreements pursuant to which the stock options have been granted and were made as an inducement material to each entering into employment with the Company in reliance of the exemption under Nasdaq Listing Rule 5635(c)(4).

    About Plus Therapeutics, Inc.

    Plus Therapeutics is a clinical-stage pharmaceutical company focused on making a positive impact on patients' lives and adding value to the healthcare system. We are a publicly-traded company on Nasdaq (PSTV, an abbreviation of ‘POSITIVE') with our headquarters in Austin, Texas and GMP-validated manufacturing facilities in San Antonio, Texas.  The location of our operations provides us with many potential strategic advantages, including proximity to world-class cancer institutions and researchers and the ability to qualify and apply for funding through the Cancer Prevention and Research Institute of Texas, or CPRIT.

      

    Our pipeline of candidate drug products includes our lead drug product candidates, RNL™ and DocePLUS™, which are being developed in the U.S. by a dedicated and energetic team of biologists, chemists, engineers, physicians and other professionals. This diverse and experienced team uses versatile and proprietary nanotechnology to reformulate and deliver chemotherapeutics and radiotherapeutics to provide meaningful benefits to patients and healthcare providers. Our technology platform serves as the foundation of our drug product pipeline and affords us the opportunity to develop additional drugs for rare cancers. More information may be found at www.plustherapeutics.com.

    Contact:

    Plus Therapeutics, Inc. 

    Andrew Sims

    VP – Chief Financial Officer, Investor Relations

    Phone: +1.619.333.4150

    Email:  

    Website: plustherapeutics.com  

    Primary Logo

    View Full Article Hide Full Article
View All PLUS THERAPEUTICS Inc. News